CAH Cardinal Health, Inc.

Here, we highlight five medical supplies stocks, MCK, CAH, BDX, MMSI and PDEX, with strong potential that investors should keep on their watchlist amid improving industry prospects.

Even though Cardinal Health (currently trading at $220.37 per share) has gained 6.8% over the last six months, it has lagged the S&P 500’s 22.1% return during that period. This may have investors wondering how to approach the situation.

AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.

AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.

Cardinal Health (CAH) closed at $220.22 in the latest trading session, marking a -1.08% move from the prior day.

McKesson (MCK) is back in focus after its share price dipped 1.2%, trailing the broader market, as investors weigh mixed earnings estimates against the company’s raised full-year adjusted EPS guidance and specialty-led healthcare footprint. Recent trading has been choppy for McKesson, with the share price slipping 3.95% over the past 30 days even after a 13.86% 90 day share price return and a 5.58% share price gain year to date. That near term hesitation sits against a much stronger backdrop,...

Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

Cardinal Health has been a powerful performer over the past several years. The question now is whether the current share price lines up with what the business is earning. With the stock pulling back slightly in the short term after a strong multi year run, investors are increasingly focused on what its earnings actually justify. Cardinal Health has returned about 378.2% over the past 5 years, which puts real pressure on the current valuation story to be supported by the earnings profile. The...

CAH's specialty-led growth, stronger EPS outlook and improving estimate momentum set up a compelling case against MCK.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

In the latest trading session, Cardinal Health (CAH) closed at $222.04, marking a -1.64% move from the previous day.

CVS Health and Cardinal Health are benefiting from healthcare growth, but differences in performance, valuation and targets shape the outlook.

CAH is expanding its MSO strategy across specialty care, with Solaris and broader services aimed at scaling physician networks.

According to the average brokerage recommendation (ABR), one should invest in Cardinal (CAH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Cencora (NYSE:COR) executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and momentum in its international businesses. Speaking at the Morgan Stanley Global Heal

CVS raises its 2026 revenue and earnings outlook, but reimbursement pressure, macro headwinds and soft front-store demand could weigh on results.

Cencora (NYSE:COR) executives highlighted the company’s specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while reaffirming the durability of its relationship with Walgreens. Chief Executive Offi

Cardinal Health (NYSE:CAH) CEO Jason Hollar said the company expects fiscal 2027 to extend the broad operating momentum it generated in fiscal 2026, with all five operating segments positioned for what he described as a “constructive” period. Speaking at the Morgan Stanley Global Healthcare Confere

Cardinal Health (NYSE:CAH) CEO Jason Hollar said the company’s fiscal 2026 performance was supported by double-digit earnings growth across each of its five operating segments, while fiscal 2027 guidance reflects continued growth from a more normalized base. Speaking at a Baird event, Hollar said t

Life sciences solutions and products provider Thermo Fisher Scientific (NYSE:TMO)’s shares have done well in September and are up by more than 8% since the 10th. On the 15th, Cramer discussed the strength in the shares in a conversation with his co-host David Faber amidst the turmoil in the AI sector on the back of […]

Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]

BTSG faces a $200M 2026 IRA revenue headwind in Home Pharmacy, but efficiency gains and technology are helping protect profitability.

Cardinal Health expects IRA pricing changes to pressure Pharma revenues while protecting profitability through compensation and durable distribution agreements.

Cardinal Health has outperformed the Health Care Services industry over the past year, and analysts are highly optimistic about the stock’s prospects.

The latest trading day saw Cardinal Health (CAH) settling at $232.36, representing a -1.08% change from its previous close.

While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a gene-editing breakthrough that could reshape medicine.

McKesson (NYSE:MCK) executives said the company’s first-quarter performance supported a higher full-year earnings outlook, citing broad-based growth across its North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions businesses. Speaking at the Morgan Stanl

Amgen trades at a cheaper valuation but carries higher leverage, while Vertex boasts pristine finances and 32% net margins, a classic trade-off between value and quality.

Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.

Amgen is profitable and paying a growing dividend, while Revolution Medicines is burning cash to fund what could be one of the most important cancer drug launches in years.

One company is generating billions in revenue and raising its dividend. The other is burning cash in pursuit of a scientific breakthrough that could change how diseases are treated.

AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.

Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.

Cardinal (CAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson & Johnson (NYSE:JNJ) or Cardinal Health (NYSE:CAH). Mad Money host Jim Cramer said: Well, I’ll tell you… I think it’s always good to look at Lilly as a stock […]

In the latest trading session, Cardinal Health (CAH) closed at $240.49, marking a -2.71% move from the previous day.

Technology is becoming a bigger part of CAH's strategy, linking distribution, specialty services and logistics through digital workflows.

McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter. The company said Precision Medicine Group would expand two areas it has id

AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]

Cencora raised its fiscal 2026 EPS outlook as specialty businesses fueled stronger profit growth despite mix, pricing and financing pressures.

Cardinal Health's generic volumes, profitable brand-to-generic conversions and Red Oak program continue to support Pharma profits.

CVS Health's strong cash generation, higher operating cash flow outlook and disciplined capital deployment support continued deleveraging in 2026.

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

CVS Health carries strong pharmacy momentum into H2 2026, with rising prescription volume, Rite Aid gains and higher profit.

In August 2026, Cardinal Health reported fourth‑quarter sales of US$63,672 million and net income of US$398 million, alongside a new US$4.00 billion revolving credit facility, a fresh US$5.00 billion share repurchase authorization, and a regular quarterly dividend of US$0.5158 per share. Together with over US$2.08 billion already spent to retire approximately 5.7% of its shares, this combination of earnings growth, expanded liquidity, and stepped-up capital returns highlights management’s...

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.